Maurine buys PTLA 47.9: Shares of Portola Pharmaceuticals ( NASDAQ:PTLA ) opened at 48.19 on Thursday.

Zacks has also given Portola Pharmaceuticals an industry rank of 89 out of 265 based on the ratings given to related companies. Analysts have set a 12-month consensus target price of $61.00 for the company and are anticipating that the company will post ($1.24) earnings per share for the current quarter, according to Zacks. One investment analyst has rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. They issued an outperform rating and a $51.00 target price on the stock. Credit Suisse assumed coverage on Portola Pharmaceuticals in a report on Tuesday, June 23rd.


Madelene:
In other Portola Pharmaceuticals news, Director Charles J.

Ryan:
On average, equities research analysts predict that Portola Pharmaceuticals will post ($4.55) earnings per share for the current fiscal year.

Kenyetta:
The business earned $2.39 million during the quarter, compared to the consensus estimate of $2.30 million.

Trudy:
The biopharmaceutical company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.07) by $0.05. During the same period last year, the firm earned ($0.76) earnings per share.

Erika:
Credit Suisse started coverage on shares of Portola Pharmaceuticals in a research report on Tuesday, June 23rd.

Celena:
During the same quarter last year, the company posted ($0.76) earnings per share.

Lettie:
The firm had revenue of $2.39 million for the quarter, compared to analyst estimates of $2.30 million.

Tameka:
We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Leah:
Portola has entered into Phase 3 clinical collaboration agreements with all of the manufacturers of direct Factor Xa inhibitors while retaining all commercial rights to andexanet alfa.

Nobuko:
Andexanet alfa has the potential to be a first-in-class antidote for anticoagulated patients who suffer a major bleeding episode or require emergency surgery.

Portola Pharmaceuticals Inc. (NASDAQ:PTLA)
//stockhand.net/us/?q=nasdaq%3Aptla&id=440351